Quantitative 7T Phase Imaging in Premanifest Huntington Disease

REFERENCES

1. 1.↵
   1. Vonsattel JP,
   2. DiFiglia M

   . Huntington disease. J Neuropathol Exp Neurol 1998;57:369–84

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Li SH,
   2. Li XJ

   . Huntingtin and its role in neuronal degeneration. Neuroscientist 2004;10:467–75

   Abstract/FREE Full Text
3. 3.↵
   1. Bohanna I,
   2. Georgiou-Karistianis N,
   3. Hannan AJ,
   4. et al

   . Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease. Brain Res Rev 2008;58:209–25

   CrossRefPubMed
4. 4.↵
   1. Aylward EH,
   2. Codori AM,
   3. Rosenblatt A,
   4. et al

   . Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord 2000;15:552–60

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Rosas HD,
   2. Goodman J,
   3. Chen YI,
   4. et al

   . Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology 2001;57:1025–28

   CrossRef
6. 6.↵
   1. Kipps CM,
   2. Duggins AJ,
   3. Mahant N,
   4. et al

   . Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study. J Neurol Neurosurg Psychiatry 2005;76:650–55

   Abstract/FREE Full Text
7. 7.↵
   1. Tabrizi SJ,
   2. Langbehn DR,
   3. Leavitt BR,
   4. et al

   . Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8:791–801

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Weir DW,
   2. Sturrock A,
   3. Leavitt BR

   . Development of biomarkers for Huntington's disease. Lancet Neurol 2011;10:573–90

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Rosas HD,
   2. Salat DH,
   3. Lee SY,
   4. et al

   . Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 2008;131:1057–68

   Abstract/FREE Full Text
10. 10.↵
    1. Dexter DT,
    2. Carayon A,
    3. Javoy-Agid F,
    4. et al

    . Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114:1953–75

    Abstract/FREE Full Text
11. 11.↵
    1. Bartzokis G,
    2. Lu PH,
    3. Tishler TA,
    4. et al

    . Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem Res 2007;32:1655–64

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Bartzokis G,
    2. Tishler TA

    . MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease. Cell Mol Biol (Noisy-le-Grand) 2000;46:821–33

    PubMedWeb of Science
13. 13.↵
    1. Bartzokis G,
    2. Cummings J,
    3. Perlman S,
    4. et al

    . Increased basal ganglia iron levels in Huntington disease. Arch Neurol 1999;56:569–74

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Chen JC,
    2. Hardy PA,
    3. Kucharczyk W,
    4. et al

    . MR of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease. AJNR Am J Neuroradiol 1993;14:275–81

    Abstract/FREE Full Text
15. 15.↵
    1. Dumas EM,
    2. Versluis MJ,
    3. van den Bogaard SJ,
    4. et al

    . Elevated brain iron is independent from atrophy in Huntington's disease. Neuroimage 2012;61:558–64

    CrossRefPubMed
16. 16.↵
    1. Haacke EM,
    2. Mittal S,
    3. Wu Z,
    4. et al

    . Susceptibility-weighted imaging: technical aspects and clinical applications, part 1. AJNR Am J Neuroradiol 2009;30:19–30

    Abstract/FREE Full Text
17. 17.↵
    1. Haacke EM,
    2. Cheng NY,
    3. House MJ,
    4. et al

    . Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 2005;23:1–25

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Haacke EM,
    2. Gollapalli L,
    3. Rosas DH,
    4. et al

    . Using SWI as a means to better visualize the caudate nucleus in Huntington's disease. In: Proceedings of 14th Annual Meeting of the International Society for Magnetic Resonance in Medicine; Seattle, Washington. May 6–12, 2006:2657
19. 19.↵
    1. Haacke EM,
    2. Ayaz M,
    3. Khan A,
    4. et al

    . Establishing a baseline phase behavior in magnetic resonance imaging to determine normal vs. abnormal iron content in the brain. J Magn Reson Imaging 2007;26:256–64

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Hammond KE,
    2. Metcalf M,
    3. Carvajal L,
    4. et al

    . Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol 2008;64:707–13

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Abduljalil AM,
    2. Schmalbrock P,
    3. Novak V,
    4. et al

    . Enhanced gray and white matter contrast of phase susceptibility-weighted images in ultra-high-field magnetic resonance imaging. J Magn Reson Imaging 2003;18:284–90

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Doan NT,
    2. van den Bogaard SJA,
    3. Dumas EM,
    4. et al

    . Texture analysis of ultrahigh field T₂*-weighted MR images of the brain: application to Huntington's disease. J Magn Reson Imaging 2014;39:633–40

    CrossRefPubMed
23. 23.↵
    1. Paulsen JS,
    2. Hayden M,
    3. Stout JC,
    4. et al

    . Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 2006;63:883–90

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Harrington DL,
    2. Smith MM,
    3. Zhang Y,
    4. et al

    . Cognitive domains that predict time to diagnosis in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 2012;83:612–19

    Abstract/FREE Full Text
25. 25.↵
    1. Zhang Y,
    2. Long JD,
    3. Mills JA,
    4. et al

    . Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am J Med Genet B Neuropsychiatr Genet 2011;156B:751–63

    CrossRef
26. 26.↵
    1. Paulsen JS,
    2. Langbehn DR,
    3. Stout JC,
    4. et al

    . Detection of Hutington's disease decades before diagnosis: the PREDICT-HD study. J Neurol Neurosurg Psychiatry 2008;79:874–80

    Abstract/FREE Full Text
27. 27.↵
    1. Duff K,
    2. Paulsen JS,
    3. Beglinger LJ,
    4. et al

    . “Frontal” behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness. J Neuropsychiatry Clin Neurosci 2010;22:196–207

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Hart E,
    2. Middelkoop H,
    3. Jurgens CK,
    4. et al

    . Seven-year clinical follow-up of premanifest carriers of Huntington's disease. PLoS Curr 2011;3:RRN1288

    CrossRefPubMed
29. 29.↵
    1. Stout JC,
    2. Paulsen JS,
    3. Queller S,
    4. et al

    . Neurocognitive signs in prodromal Huntington disease. Neuropsychology 2011;25:1–14

    CrossRefPubMedWeb of Science
30. 30.↵
    1. You SC,
    2. Geschwind MD,
    3. Sha SJ,
    4. et al

    . Executive functions in premanifest Huntington's disease. Mov Disord 2014;29(suppl 3):405–09

    CrossRefPubMed
31. 31.↵
    1. Hammond KE,
    2. Lupo JM,
    3. Xu D,
    4. et al

    . Development of a robust method for generating 7.0 T multichannel phase images of the brain with application to normal volunteers and patients with neurological diseases. Neuroimage 2008;39:1682–92

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Patenaude B,
    2. Smith SM,
    3. Kennedy DN,
    4. et al

    . A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage 2011;56:907–22

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Jenkinson M,
    2. Bannister P,
    3. Brady M,
    4. et al

    . Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 2002;17:825–41

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Buckner RL,
    2. Head D,
    3. Parker J,
    4. et al

    . A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage 2004;23:724–38

    CrossRefPubMedWeb of Science
35. 35.↵
    1. You C,
    2. Satris G,
    3. Apple A,
    4. et al

    . New sensitive measures of executive functioning in premotor Huntington's disease. Neurology 2013;80:S20.002
36. 36.↵
    1. He X,
    2. Yablonskiy DA

    . Biophysical mechanisms of phase contrast in gradient echo MRI. Proc Natl Acad Sci U S A 2009;106:13558–63

    Abstract/FREE Full Text
37. 37.↵
    1. Bilgic B,
    2. Pfefferbaum A,
    3. Rohlfing T,
    4. et al

    . MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping. Neuroimage 2012;59:2625–35

    CrossRefPubMed
38. 38.↵
    1. Hagemeier J,
    2. Dwyer MG,
    3. Bergsland N,
    4. et al

    . Effect of age on MRI phase behavior in the subcortical deep gray matter of healthy individuals. AJNR Am J Neuroradiol 2013;34:2144–51

    Abstract/FREE Full Text
39. 39.↵
    1. Murphy DG,
    2. DeCarli C,
    3. Schapiro MB,
    4. et al

    . Age-related differences in volumes of subcortical nuclei, brain matter and cerebrospinal fluid in healthy men as measured with magnetic resonance imaging. Arch Neurol 1992;49:839–45

    CrossRefPubMedWeb of Science
40. 40.↵
    1. Berg D,
    2. Youdim MB

    . Role of iron in neurodegenerative disorders. Top Magn Reson Imaging 2006;17:5–17

    CrossRefPubMed